Abstract. Rapid proliferation is one of the critical characteristics of breast cancer. However, the underlying regulatory mechanism of breast cancer cell proliferation is largely unclear. The present study indicated that sevoflurane, one of inhalational anesthetics, could significantly suppress breast cancer cell proliferation by arresting cell cycle at G1 phase. Notably, the rescue experiment indicated that miR-203 was upregulated by sevoflurane and mediated the function of sevoflurane on suppressing the breast cancer cell proliferation. The present study indicated the function of the sevoflurane/miR-203 signaling pathway on regulating breast cancer cell proliferation. These results provide mechanistic insight into how the sevoflurane/miR-203 signaling pathway supresses proliferation of breast cancer cells, suggesting the sevoflurane/miR-203 pathway may be a potential target in the treatment of breast cancer.
Introduction
Breast cancer is one of the most common cancers in women worldwide. Rapid proliferation ensures the growth and the further invasion of breast cancer (1) . Determination of the regulatory mechanism of breast cancer proliferation, eparticularly the cell cycle regulation, is important for diagnosis earlier and clinical therapy.
Previous studies showed that sevoflurane, a common anesthetic, could repress the tumorigenesis of some types of cancers. For example, sevoflurane could inhibit the migration and invasion of glioma cells by upregulating the level of miR-637 (2) . MMP-2 expression could be also repressed by sevoflurane to attenuate the migration of glioma cells (3) . Sevoflurane inhibited hypoxia-induced growth and metastasis in lung cancer cells (4) . Exposure to sevoflurane (1%) for 6 h promoted the proliferation of human colon cancer (5) . These studies showed the inhibitory function of sevoflurane on cancer initiation and development. However, whether or how sevoflurane regulates the breast cancer growth and the downstream regulatory signaling pathway remain largely unknown.
MicroRNAs (miRNAs) are small non-coding RNAs, which regulate gene expression by binding to the 3-untranslated regions (3'UTRs) of mRNAs (6) . miRNAs participate in regulating many biological processes including the embryonic development, initiation of many diseases (6) (7) (8) (9) (10) . Increasing studies have showed that miRNAs affect the proliferation, metastasis, invasion of cancer cells. Additionally, the expression level of miRNAs can also determine the pathogenesis classification, diagnosis and prognosis of cancer (11) (12) (13) . Among these miRNAs, miR-29 family have been reported to be the tumor regulator and biomarker (14, 15) . miR-106 promoted colorectal cancer cell migration and invasion by repressing the expression of DLC1 (16) . Although more and more miRNAs were identified to be involved in cancer and other diseases, the particular roles of miRNA in different context of disease remain largely unknown. miR-203 has been also reported to be as the potential marker of the early detection of cervical cancer lymph node metastases. The low level of miR-203 was related to lymph node metastasis (17) . A previous study showed that miR-203 repressed proliferation and induced apoptosis of colorectal cancer cells by post transcriptionally deregulating CPEB4 (18) . However, prostate carcinoma patients with high miR-203 level showed lower average survival time than those with low miR-203 level (19) . Although miR-203 showed different regulatory function in different cancers, miR-203 can be the critical regulator of some cancers and even the potential marker of diagnose. However, the function of miR-203 on regulating the proliferation of breast cancer cells remains largely unknown.
In the present study we made the hypothesis that sevoflurane repressed the proliferation of breast cancer. In order to investigate the mechanism of proliferation regulation, we performed the cell cycle analysis and detected the miRNAs function and related regulatory signaling. This study may uncover the function of sevoflurane on regulating breast cancer cell proliferation and suggested the potential therapeutic target of miRNA for cancer prevention and treatment.
Materials and methods
Cell culture and sevoflurane treatment. Breast cancer cells were purchased from the Cell Bank Type Culture Collection of Chinese Academy of Sciences (CBTCCCAS; Shanghai, China) and cultured in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) with fetal bovine serum (10%) (Gibco; Thermo Fisher Scientific, Inc.) at 37˚C, in a humidified atmosphere containing CO 2 (5%). The culture medium was added 100 U/ml of penicillin sodium (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA), and 100 mg/ml of streptomycin sulfate (Invitrogen; Thermo Fisher Scientific, Inc.). Cells were exposed to 2% sevoflurane for 6 h as previously described (5, 20) . 2% sevoflurane is clinically relevant and regulates the proliferation of human hepatocellular carcinoma cells (21) . CO 2 , O 2 and sevoflurane concentration was monitored by A Drager Vamos gas analyzer (Drager, Lübeck, Germany). The cells used for each experiments were culture in the 6 wells dish and seeded at the concentration of 1x10 5 
/well.
Overexpression and inhibition of miRNA. Pre-miR-203, miRNA-203 inhibitor and the control miRNA were synthetic nucleic acids (Biotend, Shanghai, China). Pre-miRNAs can be processed by enzymes to become mature miRNAs. miRNA inhibitor has reverse complementary sequence of the miRNA. Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) was used for transfection of the pre-miRNA or inhibitor into cells which grown to approximately confluence (80%). 
MTS proliferation assay. Proliferation was detected by

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)
. RNAiso (Takara Bio, Inc., Otsu, Japan) was used for isolating total RNA. For reverse-transcription of miRNA, miRNA specific stem-loop reverse-transcription primer (Ribobio, China) was used. The amount of gene expression (2-ΔΔCt) was normalized tothe endogenous nuclear RNA U6 using miRNA-specific primers (RiboBio Co., Ltd., Guangzhou, China). For mRNA RT-qPCR, cDNA was reverse-transcribed from mRNA by M-MLV Reverse Transcriptase (Takara) using random primers and oligo (dT) primers. The quantification of level of target gene expression (2 -ΔΔCt ) was normalized to the endogenous GAPDH mRNA (7, 22) . The reaction conditions of PCR were according to the SYBR-Green qPCR Mix instruction (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Statistical analyses. For statistical analyses, student's t-test or one way ANOVA with Boferroni's correction was used. The values were showed as the mean ± SD. P<0.05 was defined as statistically significant.
Results
Sevoflurane inhibits the proliferation of breast cancer cells.
In order to determine the function of sevoflurane on breast cancer cells proliferation, MDA-MB-231 or MCF-7 cells were treated with sevoflurane (2%) for 6 h and cultured for another 24, 48 and 72 h without sevoflurane. The proliferation capacity was detected by MTS assay. The results showed that sevoflurane decreased proliferation of MDA-MB-231 or MCF-7 cells (Fig. 1A) . The BrdU incorporation assay in MDA-MB-231 cells was performed and cells treated with sevoflurane (2%) for 6 h and then cultured for another 24 h without sevoflurane were found showing decreased proliferation capacity (Fig. 1B) . We further detected the cycle-related genes in MDA-MB-231 cells and found that the level of cyclin D, cyclin E, which have been reported to be the critical regulatory genes of G1 phase, were significantly downregulated. In contrary, the expression of Rb1, P21, P27, the cell cycle-inhibiting genes, were upregulated compared with control group on both mRNA and protein levels (Fig. 1C) . Flow cytometry assay showed that proportion of cells at G1 phase was increased and cells at the S, G2/M phase was decreased after treating by sevoflurane in MDA-MB-231 cells (Fig. 1D) .
miR-203 is upregulated by sevoflurane and repressed the proliferation of breast cancer cells.
Using RT-qPCR, we detected that miR-203 could be upregulated in MDA-MB-231 cells treated with sevoflurane ( Fig. 2A) . To determine the effect of miR-203, we transfected the pre-miR-203 into MDA-MB-231 cells and found that miR-203 significantly repressed the proliferation in both MDA-MB-231 and MCF-7 cells (Fig. 2B and C) . In contrast, transfection of the miR-203 inhibitor whose efficiency was determined by detecting the target gene SNAI2 level (23) promoted the proliferation of MDA-MB-231 and MCF-7 cells detected by MTS assay (Fig. 2B) . BrdU incorporation assay in MDA-MB-231 cells also indicated the similar results (Fig. 2C) . Expression level of cyclin D, cyclin E was downregulated in cells transfected with pre-miR-203 (Fig. 2D) and upregulated in the MDA-MB-231 cells transfected with miR-203 inhibitor (Fig. 2E) . The expression of P21, P27, Rb1 was upregulated in cells transfected with pre-miR-203, while downregulated in cells transfected with miR-203 inhibitor ( Fig. 2D and E) . Flow cytometry assay showed that proportion of cells was increased at G1 phase and decreased at the S and G2/M phase in MDA-MB-231 cells transfected with pre-miR-203 (Fig. 2F) . Whereas, the proportion of cells was decreased at G1 phase and increased at the S and G2/M phase in MDA-MB-231 cells transfected with miR-203 inhibitor (Fig. 2F) .
miR-203 inhibitor rescues the effects of sevoflurane in breast cancer cells.
In order to determine whether miR-203 actually mediated the function of sevoflurane, we performed the rescue experiment (Fig. 3) . Results indicated that miR-203 inhibitor significantly attenuated the proliferation repression caused by sevoflurane treatment in both MDA-MB-231 (Fig. 3A and C) and MCF-7 cells (Fig. 3B) . miR-203 inhibitor also resisted the effect of sevoflurane on the expression of cell cycle-related genes in MDA-MB-231 cells (Fig. 3D) . Flow cytometry assay showed that, compared with MDA-MB-231 cells treated with sevoflurane, the increase of cells at G1 phase and the decrease of cells at the S and G2/M phase can be reversed by miR-203 inhibitor in MDA-MB-231 cells (Fig. 3E) . 
Discussion
Breast cancer is the world's first serious malignant neoplasm which threaten the health of female, it had exceeded the cervical cancer and became the first factor of cancer deaths in women. Proliferation, invasion and metastasis are the important characteristic of breast cancer. Disclosing the underlying mechanism of breast cancer development will be helpful to find potential therapeutic approaches to treat breast cancer. Although sevoflurane is commonly used as an inhalational anesthetic during the surgery of cancer patients, evidences have demonstrated its effects on cell growth. A previous study reported that volatile anaesthetics, such as isoflurane, sevoflurane or desflurane, enhanced the metastasis-related cellular signaling including CXCR2 in ovarian cancer cells (24) . Sevoflurane could induce the apoptosis of lung alveolar epithelial cells (25) . Sevoflurane also was reported to regulate the expression of cyclin D1, but not p27Kip1 in the hippocampus (26) . These studies suggested the complicated effects of sevoflurane on regulating the proliferation and cell cycle. It is significative to investigate the mechanism of regulatory effect of sevoflurane on different cells. In our study, we found that sevoflurane could significantly suppress the proliferation of MDA-MB-231 and MCF-7 breast cancer cells. Cells treated with sevoflurane arrested at the G1 phase. Our results showed that sevoflurane could be a potential therapeutic agent to prevent or treat breast cancer by regulating the cell cycle. Some other studies showed that sevoflurane possessed the opposite function, which suggested the complex effects of the sevoflurane on different cancer cells.
Among tumor-related miRNAs, miR-203 is one of the critical miRNAs that plays important roles in regulating proliferation of several types of cells. miR-203 reduced the PDGF-stimulated proliferation in human airway smooth muscle (HASM) cells (27) , and formed the JNK-miR-203-p63 signaling to regulate keratinocyte proliferation and differentiation (28) . miR-203 also plays important roles in cancerigenesis. miR-203 has been reported to be the tumor suppressor in osteosarcoma (29) . miR-203 also directly targeted oncogene ADAM9 and long non-coding RNA HULC to inhibit the hepatocellular carcinoma cell proliferation and metastasis (30) . In this study, we found that overexpression of miR-203 could suppress the proliferation and inhibition of miR-203 promoted the proliferation of MDA-MB-231 and MCF-7 breast cancer cells. Notably, miR-203 could be upregulated by sevoflurane treatment in breast cancer cells. The miR-203 inhibitor blocked the repression the proliferation of sevoflurane in breast cancer cells.
In this study, we uncovered the function of sevoflurane in regulating the breast cancer proliferation. Abnormal cell proliferation is most associated with influence of cell cycle regulation (31) . The cell cycle was arrested at G1 phase, which is indicated by change of some important cell cycle-related genes expression.
It is the first time to determine the function and mechanism of sevoflurane in breast cancer cells. miR-203 is the downstream target of sevoflurane to mediate the proliferation and cell cycle. We will further study whether there are transcription factors involved in the expression of miR-203 regulated by sevoflurane. Additionally, we will also investigate the target genes of miR-203, which regulates cell cycle. We will also need further study about more similar types of breast cancers to validate the present results to confirm the mechanism of the miR-203 mediated the function of sevoflurane. Additionally, in vitro and in vivo studies will be conducted in order to validate the current results. In summary, we demonstrated a new functional role of sevoflurane/miR-203 signaling pathway on suppressing breast cancer cell proliferation and further confirmed the influence of cell cycle regulation of G1 phase and cell cycle-related genes expression.
